Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Preferred Stock Liabilities came in at $310.6 million in Q1 2018, up 159.32% on a QoQ basis from $119.8 million in Q4 2017.
Kiniksa Pharmaceuticals International (KNSA) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 2 years of Preferred Stock Liabilities data on file, last reported at $310.6 million in Q1 2018.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $310.6 million in Q1 2018, while the trailing twelve-month figure through Mar 2018 was $310.6 million (changed N/A YoY) and the FY2017 annual result came in at $119.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $310.6 million in Q1 2018, from $119.8 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $310.6 million in Q1 2018 to a low of $119.8 million in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.56 Bn | 220.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 310.59 Mn |
| Dec 31, 2017 | 119.77 Mn |